Dihydropyranopyrimidines for the treatment of viral infections
This invention relates to dihydropyranopynmidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
1. A method of treating viral hepatitis in which the activation of TLR7 and/or TLR8 is involved in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), (II) or (III) having the structure
or a pharmaceutically acceptable salt, tautomer, stereo-isomeric form, or solvate thereof, wherein
R 1 is C 1-6 alkyl substituted by one or more substituents independently selected from hydroxyl or C 1-3 alkoxy;
R 2 is selected from hydrogen, fluorine, C 1-3 alkyl, cyclopropyl, —CF 3 , C 1-3 alkoxy or nitrile.
2. A method of treating viral hepatitis in which the activation of TLR7 and/or TLR8 is involved in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound having a structure selected from the group consisting of:
or a pharmaceutically acceptable salt, tautomer, stereo-isomeric form, or solvate thereof.
3. The method of claim 1 , wherein the activation of TLR8 is involved in the subject in need thereof.
4. The method of claim 1 , wherein R 1 is C 1-6 alkyl substituted by hydroxyl.
5. The method of claim 1 , wherein R 1 is C 6 alkyl substituted by hydroxyl.
6. The method of claim 1 , wherein R 1 is:
7. The method of claim 1 , wherein R 1 is:
8. The method of claim 1 , wherein R 2 is hydrogen.
9. The method of claim 2 , wherein the activation of TLR8 is involved in the subject in need thereof.
10. A method of activating human TLR7 and/or TLR8 in a subject, comprising administering to the subject an effective amount of a compound of formula (I), (II) or (III) having the structure
or a pharmaceutically acceptable salt, tautomer, stereo-isomeric form, or solvate thereof, wherein
R 1 is C 1-6 alkyl substituted by one or more substituents independently selected from hydroxyl or C 1-3 alkoxy;
R 2 is selected from hydrogen, fluorine, C 1-3 alkyl, cyclopropyl, —CF 3 , C 1-3 alkoxy or nitrile.
11. The method of claim 10 , wherein the compound has a structure selected from the group consisting of:
or a pharmaceutically acceptable salt, tautomer, stereo-isomeric form, or solvate thereof.